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ABSTRACT 
Recent advances in genomics and genome editing strategies have created novel 
prospects for gene therapy. Advancements in genomic sequencing able us to 
regulate the expression of pathogenic phenotype-causing genes through the 
utilization of therapeutic nucleic acids. The main obstacle for gene therapy is 
the poor cellular uptake of such therapeutics. Therefore, the major challenge in 
creating effective gene-based therapies is the development of selective and safe 
delivery vectors. Currently, the most effective and abundantly utilized gene deli-
very vehicles in clinical trials are virus-derived vectors. Despite the encouraging 
results with the viral delivery systems, concern about the safety of these vectors 
remains. Therefore, increasingly more effort have been applied into the research 
of non-viral vehicles as a safer alternative to the viral counterparts. 
Cell-penetrating peptides are short cationic and/or amphipathic peptides that 
upon the non-covalent complexation with nucleic acids can enhance signi-
ficantly nucleic acid uptake into cells. The main problems that hinder CPP 
wider application in gene delivery are non-specific and low transfection efficacy 
in vivo and poor control over the size and size distribution of the non-covalently 
formed nanoparticles.  
The aim of this research was to design more effective transfection reagents 
for the systemic in vivo gene delivery. We designed a novel peptide specifically 
for in vivo utilization by using previous knowledge about the physicochemical 
properties and internalization mechanism of different CPPs. We thereafter 
developed more efficient CPP and nucleic acid complex formulation strategy to 
prepare more uniformly sized particles to enhance gene delivery and decrease 
the risk of potential side-effects from aggregated particles. In addition, we 
tackled the problem of non-specificity of the peptide vector and incorporated 
magnetic particles into the CPP-nucleic acid complexes to enhance the efficacy 
and increase the targeted delivery into specific organs. In conclusion we deve-
loped an approach to produce non-conglomerating effective nanoparticles with 
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In recent years, important advances have been achieved in the use of genome 
editing approaches to precisely alter cellular genomes. Gene therapy can regulate 
practically any sequence in the genome and repair expression of pathogenic 
phenotype-causing genes by using therapeutic nucleic acids. Due to their size 
and anionic nature, exogenous nucleic acids need vectors to enhance their 
delivery into the diseased tissue. Although impressive accomplishments have 
been accomplished with virus-derived gene delivery vectors their utilization is 
not without risks. Increasingly more effort has been directed into the research of 
non-viral vectors. Although being safer alternatives to viral counterparts, they 
lack efficient transfection and often result in short-lived gene expression.  
Cell-penetrating peptides are one family of non-viral delivery vectors. Cell-
penetrating peptides (CPP) are short cationic and/or amphipathic peptides, 
which have been shown to significantly improve the delivery of various bio-
molecules in vivo. These non-viral peptide delivery vehicles offer a safer alter-
native to convey therapeutic nucleic acids into cells. The transport of nucleic 
acids is usually facilitated through the non-covalent attachment to the CPP. 
Although non-covalent complex formation is a great and efficient method for 
formulating stable particles for transfection, these particles display very hetero-
geneous size distribution. The size of the particle, along with other physico-
chemical properties (such as surface charge, morphology), influences the 
biodistribution of particles in vivo. Furthermore, large and aggregated particles 
can cause side-effects and increase toxicity of nanoparticles. Besides the 
heterogeneous size of formulated particles, the CPP efficient utilization is 
hindered by non-specific and low transfection in vivo. Therefore, all these 
major obstacles have to be overcome before the broader utilization of CPPs for 
in vivo gene delivery.  
The aim of this thesis was to tackle these previously described main prob-
lems of non-viral gene delivery systems. A novel effective CPP for the systemic 
delivery of DNA was designed and an improved formulation approach to 
prepare stable and uniformly sized particles was developed. Incorporation of 












1. LITERATURE OVERVIEW 
1.1. Gene therapy 
Recent advancements in genomics have able us to regulate the expression of 
almost any gene in the genome through the introduction of exogenous nucleic 
acids (NA) into cells. Therefore, gene therapy can be utilized to regulate the 
expression of the pathogenic phenotype-causing genes for therapeutic purposes. 
In addition to double-stranded DNA vectors which is often used as a therapeutic 
agent to replace defective genes in patients suffering from genetic disorders, 
small oligonucleotides can also be utilized to regulate the abnormal gene 
expression. These include small single stranded antisense oligonucleotides which 
can be used to correct aberrant splicing in many genetic disorders (such as 
Duchenne muscular dystrophy)(1). Additionally, double-stranded interfering 
RNAs (siRNAs) or more complicated system such as plasmid DNA vectors 
which encodes small hairpin RNAs which then are processed into siRNAs inside 
cells which can subsequently utilized for RNA interference to regulate the 
pathogenic gene expression at the post-transcriptional level(2).  
The idea of gene therapy arose initially during the 1960s with the develop-
ment of genetically marked cell lines(3–6) and with better understanding of 
mechanism of cell transformation by the papovaviruses (6–8). Although gene 
therapy offers a great promise, the main problem lies in the development of 
efficient gene-delivery vehicles which can deliver these therapeutic nucleic 
acids into the diseased tissue.  
In 1990 the FDA approved the first clinical trial of gene therapy with attempt 
to treat adenosine deaminase deficiency, a monogenetic disease leading to severe 
immunodeficiency(9). One of the two patients exhibited a temporary response, 
but the successfulness of the gene therapy is debatable as she received simul-
taneously enzyme replacement therapy with polyethylene glycol adenine 
deaminase (9,10). After this initial gene therapy attempt further gene transfer 
trials were started for several diseases (10) until the 1999 when the patient died 
from multiple organ failure after immune system responded to high dose 
adenovirus administration(11). This unfortunate incident demonstrated the first 
time the need for safer gene delivery systems. The first real successful gene 
therapy was in 2000 when Cavazzana-Calvo et al was able to provide full 
correction of disease phenotype in human severe combined immunodeficiency 
(SCID)-X1 disease(12). Although the study experienced a major setback when 
25% of the treated boys developed leukemia due to insertional mutagenesis, it 
led to the public discussion about the risks of gene therapy and the development 
of sensitive polymerase chain reaction techniques to detect viral integration 
sites, thereby considerably increasing the safety of integrating vectors(13). 
Despite some success (shown in Table 1), many challenges remain to fully 
utilize the potential of gene therapy. The main obstacles are the persistent issues 
of safety and delivery. Currently utilized vectors for nucleic acid delivery can 
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be divided into viral and non-viral vectors. Although viral vectors are the most 
efficient and extensively used delivery vehicles in clinical trials they can exhibit 
serious side-effects. Therefore, a lot of energy has been applied for designing 
non-viral vectors for safer gene delivery. Despite the great progress made with 
delivery vectors the lack of efficient delivery of therapeutic nucleic acids still 
hindrance the practical utilization of gene therapy. 
 
Table 1. Gene therapy products approved for marketing. 
Product The objective Vector Approval Ref 
Gendicine Gene therapy-based 
product for the clinical use 
for the treatment of head- 
and neck squamous cell 
carcinoma 
adenoviral vector, 
wherein the E1 gene is 
replaced with a human 
p53 cDNA 
2003 (14) 
Glybera The European Medicines 
Agency approves the gene 
therapy Glybera for the 




viral vector engineered 
to express lipoprotein 
lipase in the muscle 
tissue 
2012 (15) 
Strimvelis the European Commission 
granted the first market 
approval for Strimvelis for 
the treatment of adenosine 
deaminase-deficient 
(ADA) severe combined 
immunodeficiency disease 
autologous CD34+ 
enriched cell fraction 
that contains CD34+ 
cells transduced with 
retroviral vector that 
encodes for the human 
ADA cDNA sequence  
2016 (16) 
Luxturna In 2018, Spark 
Therapeutics could market 
a product for an inherited 
retinal disease 
AAV2 vector containing 





1.1.1. Gene therapy in cancer 
Gene therapy helps to eliminate cancer by delivering nucleic acids to express pro-
apoptotic proteins or substitute mutated genes, downregulate or silence onco-
genic pathways, produce anti-cancer cytokines and activate the immune system 
against cancer(18). In combination with chemotherapy, gene therapy can be 
utilized by delivering therapeutic nucleic acid against a chemotherapeutic 
resistance pathway(18).  
Targeting oncogenes is often used for cancer gene therapy. Mutations, 
amplifications, or chromosomal rearrangements in normal genes can give arise 
to oncogenes that are important for carcinogenesis. Among others, the three 
RAS genes are the most frequently mutated gene family in cancer and are found 
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in around 25% of human tumors(19). RAS genes belong to the group of 
eukaryotic genes that are necessary for cell proliferation and differentiation(19). 
Therefore, this oncogenic activity of RAS genes is considered as very potential 
molecular target for various cancer gene therapies.  
Another group of oncogenes are transcription factors. Aberrant activation of 
transcription factors alters expression of multiple gene sets associated with 
tumor development and progression. Therefore, targeting transcription factor 
can be utilized to design therapeutics for cancer gene therapy. One of the 
potential molecular targets for the cancer therapy is the transcription factor p53 
tumor suppressor gene that regulates the pathways of cell-cycle arrest, apoptosis, 
and DNA repair(18,20). p53 mutation occurs in over half of all human tumors 
and even with tumors that have wild-type p53, the pathways of p53-induced 
cell-cycle arrest and apoptosis are usually deficient(20,21).  
As tumor angiogenesis is important for creation of new blood vessels and for 
tumor mass to grow larger than a few millimeters, other gene therapy strategy is 
to alter the function of angiogenic factors (22,23). This is achieved either by 
inhibition of production or function of pro-angiogenic cytokines or by delivering 
genes that encode inhibitors of angiogenesis to suppress tumor growth(24). 
There are various potential targets such as vascular endothelial growth factor(25), 
basic fibroblast growth factor, platelet-derived growth factor and others(23).  
An efficient method for cancer therapy is to facilitate genetically-modified 
T-cells for antitumor effect. Adoptive cell therapy is personalized cancer therapy 
which use patient immune system for direct anticancer activity(26). Adoptive 
cell therapy can utilize either natural host tumor-reactive lymphocytes or host 
cells that have been genetically engineered with antitumor T cell receptors or 
chimeric antigen receptors(26). The first successful clinical application of 
adoptive cell gene therapy was reported in 2010 when treatment with cells 
expressing anti-CD19 chimeric antigen receptors in patient with refractory 
lymphoma resulted in cancer regression(27). 
Up to date, cancer is by far the most common disease treated by gene therapy. 
It composes over 64% of all ongoing clinical gene therapy trials worldwide(28). 
The first gene therapy-based product was Gendicine for treatment of head- and 
neck squamous cell carcinoma(14). This was followed by Philippine in 2007 
when Rexin-G was approved for marketing to treat solid tumors(29). Rexin-G, 
is a tumor-targeted retrovector encoding an N-terminal deletion mutant of the 
cyclin G1 gene with antineoplastic activity(29). Ten years later, in 2017 FDA 
approved genetically-modified autologous T-cell immunotherapy Kymriah for 
patients with acute lymphoblastic leukemia(30). Marketing of these gene 
therapy-based products demonstrates already the potential of gene therapy for 




1.2. Gene delivery systems 
The poor gene delivery is the limiting factor for most in vivo gene therapies. 
Carriers used for systemic in vivo gene delivery can be divided broadly into 




1.2.1. Viral vectors 
Various viruses have been studied for development of new gene therapy carriers, 
such as adenovirus, lentivirus, herpes simplex virus, adeno-associated virus and 
baculovirus. Viruses have evolved various mechanisms for overcoming cellular 
barriers to efficiently transport their genomes inside cells and achieve very high 
gene expression. Thus, it is not surprising that viral vectors are most commonly 
utilized carriers in gene therapy trials. Over half (69%) of gene vectors in 
clinical trials are viral vectors(31). Actually, adenovirus was the first effective 
gene delivery vector and it is the most commonly used vector in worldwide in 
clinical trials, accounting for >20% of all vectors used in gene therapy trials(31). 
In addition to adenoviruses, adeno-associated virus vectors can infect a wide 
range of cell types and transfect both dividing and non-dividing cells and at the 
same time demonstrate only low immunogenic profile(32). Although viral 
carriers are very efficient at transfection, some of the major obstacles of using 




1.2.2. Chemical compounds for nucleic acid non-viral delivery 
Compared to viral vectors non-viral gene delivery vehicles usually exhibit lower 
immunogenicity, higher packaging capacity and have the potential for scale-up 
manufacture. On the other hand, current non-viral vectors are not able to 
achieve as high gene transfection efficiency as viral counterparts.  
The most commonly used materials in non-viral vectors are lipids (such as 
sphingolipids), cationic polymers (mainly polyethyleneimine(33), chitosan(34), 
pDMAEMA dendrimers(35)), peptides (poly-L-lysine(36), poly-arginine(37)), 
various inorganic components(38) (such as iron oxide, silica, gold) and combi-




Figure 1. The most broadly used non-viral gene delivery vectors. These includes 
sphingolipids commonly used to prepare liposomes, polyethyleneimine (PEI), poly-L-




1.3. Cell-penetrating peptides 
Cell-penetrating peptides (CPPs) are short peptides that can penetrate and 
deliver various macromolecules through tissue and cell membranes. CPPs 
efficiently improve the intracellular delivery of various macromolecules such as 
pDNA(39), oligonucleotides(40), siRNA(41), peptide nucleic acids(42) and 
proteins(43). CPPs consist of around 30 amino acids and can be broadly divided 
into three groups based on physical-chemical properties of peptides(44,45): 
1. cationic peptides, 
2. amphipathic peptides, 
3. hydrophobic peptides. 
Most CPPs are characterized as amphipathic and/or positively charged 
peptide at physiological pH. CPPs are known to utilize both energy-dependent 
endocytosis and energy–independent direct translocation internalization methods. 
The selection of internalization pathway depends on cell lines and their con-
fluency, concentration of peptide, environment and delivered cargo(45). At 
standard concentrations of CPPs which are utilized to deliver nucleic acids in 
cell culture experiments, the main entrance mechanism is endocytosis(44). All 
different pathways of endocytosis and they co-occurrence have been observed 
with CPPs, including clathrin- and caveolae-mediated endocytosis, macropino-
cytosis and phagocytosis(44,46–48). 
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1.3.1. Origins of cell-penetrating peptides 
The first indication that proteins can translocate through biological membranes 
was in 1988 when rapid uptake in cell culture of tat transcription-transactivating 
protein of HIV was observed(49,50). Thereafter, three years later the Drosophila 
antennapedia gene homeobox (pAntp) polypeptide was shown to internalize 
into nerve cells(51). One year later, the sequence of pAntp was shortened and 
peptide of 16 amino acids in length from the third helix of the homeodomain 
was discovered to enter the cells(52). After discovery of these protein-derived 
peptides hundreds of CPPs have been synthesized. Naturally occurring proteins 
have been altered yielding so called chimeric CPPs such as Transportan (53), 
MPG(54), Pep-1(55) and M918(56). In addition, completely synthetic peptides 
have been designed such as polyarginines(37), CADY(57) and MAP(58). 
 
 
1.3.2. Transportan-derived peptides 
Transportan (TP) is a 27 amino acid-long peptide containing 12 highly con-
served amino acids from the amino terminus of the neuropeptide galanin con-
nected via a lysine with wasp venom peptide toxin mastoparan in the carboxyl 
terminus(59) (shown in Figure 2). To find the exact region of the TP sequence 
that is essential for the membrane translocation property of the peptide various 
deletion analogues of TP have been investigated(60). From various synthesized 
TP analogues the peptide TP10 which lacks first six first amino acids of  
N-terminus of TP demonstrated efficient penetration through cell membrane. 
Furthermore, this deletion decreased binding affinity towards galanin receptors 
and abolished modulation of basal GTPase activity. This is essential for 
avoiding the potential side-effects of Transportan- derived CPPs. This deleted 
new analogue TP10 lead to designing of multiple TP-based CPPs named 
PepFects (PF) and NickFects (NF). 
 
 
Figure 2. Design of Transportan and the main Transportan-derived peptides over the 
past years. a.* indicates the succinylated trifluoroquinoline based derivative. 
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1.3.3. PepFects 
One of the first effective modifications of TP10 was stearylation of N-terminus 
of the peptide yielding PepFect3 (PF3) which reduced the toxicity and increases 
TP10-mediated splice correction approximately 30-fold compared to non- 
stearylated TP10(61). Stearylation strategy was applied as results of Futaki and 
colleagues showed significantly enhanced transfection efficacy of stearylated 
polyarginine(62). 
Next, PF3 sequence was further modified by changing the sequence and by 
replacing lysines with ornithines to create leucine-zipper motif to enhance 
peptide binding with nucleic acid and increase the transfection(63,64). The 
ornithine introduction was inspired by Ramsay et al. results which demonstrated 
10-fold higher transfection efficacy of polyornithine and stronger complex 
formation with pDNA compared to polylysine peptide(65). The yielded peptide 
PF14 is one of the most efficient peptide of our group and standardly used 
transfection regent for SCO, siRNA and pDNA delivery in vitro or in vivo. 
Similarly to other CPPs TP-derived peptide utilize mainly endocytosis path-
ways to deliver cargo into cells. Therefore to enhance endosomal escape pH 
titratable trifluoromethylquinoline group was attached covalently to PF3 
sequence(66). The created peptide PF6 formed stable complexes with siRNA 
and demonstrated high RNAi response in various cell cultures with different 
confluency and even in vivo. 
Various other PF analogues have been synthesized and investigated to further 
enhance nucleic acid delivery, such as PF15(67) which contains combined 
modifications from PF14 and PF6 or PF14 analogues with different fatty acid 




The first Nickfect (NF) peptides synthesized were stearylated TP10 analogues 
where isoleucine in the TP10 sequence was substituted with threonine and/or 
additionally phosphorylated at different sites in the sequence of the peptide(69). 
The yielded peptides NF1 and NF2 exhibited significantly greater splice cor-
rection in the cell culture compared to the parental TP10 analogue. Few years 
later next efficient transfection reagent NF51 with incorporated branched 
structure into the stearylated TP10 sequence backbone was designed(70). The 
physicochemical and internalization studies of these NF analogues complexes 
with nucleic acids(71) lead to the design of NF55 peptide for specifically in 
vivo systemic gene delivery(72). 
Continuous studies are underway to further improve NF utilization in vivo 
such as incorporation of histidines to make the peptides pH-responsive and 
therefore improve their interaction with cell membrane and escape form endo-
somes through so called proton sponge effect(73).  
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1.4. Barriers for non-viral in vivo gene delivery 
Despite a century of continues discovery and development, todays therapeutic 
formulations are not capable of delivering nanoparticles specifically at sites of 
interest after systemic administration(74). Furthermore, gene vectors confront 
multiple biological barriers during systemic gene delivery. Therefore, site-
specific delivery of therapeutics will not be efficient unless design of nano-
particles considers all of the biological barriers that delivery reagents encounter 
upon intravenous administration.  
The biggest obstacles for in vivo systemic gene delivery today are (shown in 
Figure 3): 
1. Serum lability of nanoparticles 
2. Nonspecific distribution and inadequate accumulation of nanoparticles into 
the target organ and cells. 
3. Internalization of nanoparticles into cells and trafficking into the nucleus. 
 
 
1.4.1. Serum lability of nanoparticles 
First, the size of nanoparticle dictates the bio-distribution and pharmacokinetics 
of the particle after the administration and it has been shown that smaller than 
10 nm in diameter vectors are filtered out of circulation by the kidneys and 
particles over 200 nm by mononuclear phagocyte system(74,75). In general, 
nanoparticles ranging from 10 to 200 nm in diameter are considered ideal for 
avoiding the renal clearance or accumulation into the liver and spleen(74). 
After intravenous administration, nanoparticles encounter a harsh environ-
ment of blood which consist of sugars, salts, plasma proteins, and immune 
cells(76,77). As non-viral vectors are generally formed through assembly of the 
vector and nucleic acids via electrostatic interaction these interactions are 
weakened at this high salt concentrations causing complex to disassemble and 
expose nucleic acids(77). Exposed nucleic acids are thereafter very prone to fast 
degradation by serum nucleases(77,78). It has been even reported that the half-
life of free pDNA can be as short as only about ten minutes in mouse whole 
blood(78). In addition, serum may also cause nanoparticle aggregation into 
large particles, which can lead to opsonization of the vector and thereby 
clearance by mononuclear phagocytic system. This aggregation of nanoparticles 
in serum can also lead to severe pulmonary embolism(79). The adsorption of 
plasma proteins onto the surface of nanoparticle depends on many factors such 
as the size, surface charge and chemistry and hydrophobicity of particle(74,80). 
Therefore, surface charge and functionalization of the particle significantly 
influence the circulation halftime of the nanoparticle. Highly cationic particles 
have been shown to be opsonized and subsequently cleared by the phagocytic 
cells at greater extent than negatively charged or neutral particles(74,81). 
Moreover, nanoparticles with different surface functionalization display diverse 
in vivo bio-distribution and circulation time and therefore surface of the particle 
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has been modified to prolong the half-life of the particle in blood. These 
alterations include incorporation of inert polymers (such as PEG (polyethylene 
glycol))(82) or covering the surface of the particle with various biomolecules 
(for example membrane glycoprotein CD47 peptide and extracted cell memb-
rane) to biomimetic the particle and prevent protein adsorption(83,84). After 
serum proteins cover the nanoparticles and form so called protein corona the 
biological efficiency of the particles are decreased and usually only the liver and 
lungs are transfected non-specifically (77,85,86). Opsonization also hinders the 
active-targeting (such as using the targeting or shielding moieties) strategies and 
adhered protein corona masks targeting ligands which consequently results with 
reduction in specificity(74). This has been demonstrated by Salvati et al. with 
transferrin-functionalized nanoparticles that lost their targeting capabilities 
when a biomolecule corona adsorbed on the surface(87).  
Figure 3. Graphical representation of the extra- and intracellular barriers faced by non-
viral gene therapies following systemic delivery (from McCrudden and McCarthy et al. 
2013 (88) Cancer Gene Therapy – Key Biological Concepts in the Design of 
Multifunctional Non-Viral Delivery Systems, Gene Therapy – Tools and Potential 
Applications, Dr. Francisco Martin (Ed.), InTech).  
 
 
1.4.2. The nonspecific distribution and inadequate accumulation  
of nanoparticles into the target tissue 
After reaching to the targeted organ or diseased tissue other extracellular barriers 
exist depending on the targeted tissue and/or the state of the disease. For 




must pass tight junctions between capillary endothelial cells in the blood brain 
barrier (BBB) capillaries(89,90). In addition, endothelial cells express high 
levels of active efflux transport proteins such as the P-glycoprotein pumps that 
quickly remove any foreign substance that bypasses the BBB (91). In contrast to 
tight junctions between endothelial cells in brain stable and long circulating 
nanoparticles are expected to passively accumulate in the tumor via extra-
vasation through leaky vasculature. This kind of enhanced permeability of 
particles through fenestrated vasculature and endothelial dysfunction is known 
as enhanced permeability and retention (EPR) effect (92,93). This disorganized 
vasculature is very characteristic to tumors but it is not unique phenomena only 
to cancers as fenestrated vasculature has been described with infection(94) and 
with heart failures(95). Although description of the EPR effect by Maeda and 
Matsumura et al.(93) was the foundation of many macromolecular therapeutics 
designs it was soon discovered that elevated intratumoral pressure from 
vascular enhanced permeability and dysfunction of lymphatic vessels prevented 
the delivery of nanoparticles into distal regions in tumor tissue(96). The lack of 
ability of particles to reach into distal parts of the tumor greatly reduces the 
effectiveness of therapeutics(97). 
 
 
1.4.3. Internalization of nanoparticles into cells and  
trafficking into the nucleus 
After nanoparticles pass various extracellular barriers the intracellular barriers 
remain. The first obstacle is the internalization of particles through cell 
membrane. Depending on the properties of nanoparticles various internalization 
pathways are used and the fate of internalized vector depends largely on uptake 
mechanism(98). Nanoparticles are not able to diffuse through cell membrane 
due to their size, surface charge or other physicochemical properties and there-
fore require an active transport. Earlier studies indicated non-endocytotic inter-
nalization methods for many non-viral vectors. For example, studies with 
lipoplexes indicated the direct release of DNA into cytosol via fusion between 
the lipids and the plasma membrane(99) and with cell-penetrating peptides 
energy-independent direct penetration was first proposed as main internalization 
method(46). Although, it is now believed that endocytosis is the essential 
entrance mechanism for these vectors. Various non-viral vectors are known to 
enter into cells mainly via different endocytosis pathways(100–105). The pre-
dominantly utilized internalization pathway for nanoparticles is endocytosis via 
clathrin-coated vesicles(98). As the endocytosis is the main entrance pathway 
the biological efficacy of delivered cargo is greatly dependent whether particles 
can escape from intracellular vesicles and therefore avoid lysosomal degra-
dation or recycling of the vector back to the cell surface. Various modifications 
to non-viral carriers have been made to improve the release from endosome, for 
example addition of pH-sensitive fusogenic lipids(106) and peptides(107). After 
release from endosomes the DNA must then dissociate from carrier in cytosol 
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or even close to the nuclear membrane for nuclear transfection. Even when 
vectors reach from endosomes to cytosol the carried nucleic acids will be then 
vulnerable to cytoplasmic nucleases. The half-life of pDNA in cytoplasm has 
been shown to be between 50–90 min(108). The import of nanoparticles into the 
nucleus occurs through nuclear pore complex and only molecules less than 40 
kDa and 10 nm size in diameter are able to diffuse through pores(109). Since 
even the condensed pDNA is larger it causes poor transfection of non-dividing 
cells. The importance of nuclear transfection has been also demonstrated by 
Pollard and co-workers when they observed significantly increased reporter 




1.5. CPP and nucleic acid nanoparticles 
1.5.1. Vectorization of nucleic acids with CPPs for the transfection 
There are mainly two ways to form CPP/nucleic acid complexes either cova-
lently or non-covalently. In covalent coupling most often, a disulfide bond but 
also ester and peptide bonds are used to conjugate cargo onto peptide(111–113). 
This kind of linkage yields more stable and defined complexes. These stable 
and uniformly sized nanoparticles are more suitable for in vivo utilization as 
these particles exhibit longer circulation time and do not non-specifically 
accumulate into liver, lungs or renal tissue depending on their size(74). Cova-
lent strategy is advantageous for delivering uncharged nucleic acids as peptide 
nucleic acid and phosphorodiamidate morpholino oligomer, but it is not suitable 
for the transporting of pDNA and siRNA(114). On the other hand, non-covalent 
formulation process is less expensive and only simple co-incubation of peptide 
and nucleic acid is needed. In non-covalent complex formation, the positive-
charge bearing peptide is used to condense negatively charged nucleic acids into 
the particle mainly via electrostatic interaction (shown in Figure 4). This kind of 
nanoparticle assembly is widely used for transfecting cells with oligonucleo-
tides, siRNA, splice-correcting oligonucleotides (SCO) and plasmid DNA with 
various poly-cationic molecules such as poly-lysine, chitosan, cationic lipids 
and polyethyleneimine(115). Although non-covalently formed complexes might 
not exhibit so defined homogenous size distribution as covalently linked 
counterparts. This heterogenous size distribution of non-covalent complexes 
could hinder their further utilization in vivo because of the potential side-effects 




Figure 4. Graphical illustration of non-covalent complexes of CPP and nucleic acids 
(A) and covalent complexes (B), a. demonstrates the disulfide and b. amide bond 
between CPP and nucleic acid. Modified figure from Veiman et al. 2015(116). 
 
The first efficient CPP mediated oligonucleotide transfection in vivo was 
achieved through covalent attachment of Galanin receptor 1 (GalR1) antisense 
peptide nucleic acid to Transportan or Penetratin CPP(117). After intrathecal 
administration of these CPP constructs GalR1 receptors were specifically down-
regulated in rat brain. Thereafter many groups have covalently coupled 
phosphorodiamidate morpholino oligomers to various CPPs to correct the 
splicing of dystrophin mRNA in the dystrophinopathy mdx mouse model 
(118,119).  
After the discovery of Divita group that CPPs can non-covalently form 
particles with negatively-charged nucleic acid, greater extent of transfection 
studies have utilized the electrostatic forces between peptide and nucleic acids 
to facilitate the delivery(54). In addition to electrostatic forces, hydrophobic 
interactions have been also shown to be participating in non-covalent comp-
lexation of particles(120,121). This non-covalent particle formulation method 
enables to avoid laborious chemical conjugation of construct and transfect 
larger nucleic acids into cells. Non-covalent formulation method has been 
widely used to delivery different nucleic acids such as pDNA(122), siRNAs(123) 
and oligonucleotides(114) into various organs in vivo.  
 
 
1.5.2. Common modifications of CPPs to enhance  
the in vivo gene delivery  
To conquer biological barriers and enhance in vivo transfection various modi-
fications to CPP have been utilized to design more suitable vectors. Some of 
these modifications which have been introduced into the Transportan-derived 
CPPs include: 
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1. The incorporation of hydrophobic moieties and alteration of amphipathicity 
of the peptide to increment the interaction between cell membrane and CPP 
particles. 
2. Attachment of inert polymers to enhance the circulation time of the peptide 
in blood 
3. Addition of shielding moieties to the peptide to enhance the transfection 
specificity and increase the half-life of the peptide 
4. Conjugation of the CPP to the targeting moiety to increase the cell or tissue 
specific transfection 
5. Incorporation of magnetic iron oxide for more efficient targeting of CPP-
nucleic acid particles 
 
 
1.5.2.1. The incorporation of hydrophobic moieties and alteration  
of amphipathicity of the peptide to increment the 
interaction between cell membrane and CPP particles. 
Incorporation of hydrophobic moieties and increment of the amphipathicity of 
the peptide have been utilized to enhance the transfection. The enhancement of 
hydrophobicity of the peptide has been shown to improve the CPP and nucleic 
acid (NA) complexation and transfection. Futaki et al. and Khalil et al. were 
first to demonstrate that incorporation of stearyl moieties to polyarginine 
condensed DNA into stable particles(62,124). These stearylated peptide-NA 
particles were able to adsorb on to the surface of the cell membrane due to the 
increased hydrophobic interactions between the particles and cell membrane 
and thereby improve the transfection efficacy. Thereafter, multiple studies have 
demonstrated the improved transfection after increment of CPP hydropho-
bicity(61,68,125,126). Another way to improve transfection efficacy of CPPs is 
to increase the helicity and amphipathicity of the peptide. This has been 
illustrated nicely with the first synthetic CPP MAP (Model Amphipathic 
Peptide) peptide. The alteration of MAP peptide sequence (to modify the 
amphipathicity of the MAP peptide) showed that the positive charge is not the 
only factor for the penetration and that helical amphipathicity was important for 
these peptides to cross the plasma membrane(127). Disruption of the helicity of 
the peptide significantly decreased the translocation of the peptide into cells. 
Thereafter, various studies have used tuning of the amphipathicity of the 
peptide to enhance cellular uptake efficiency of the peptide (128). In addition, 
Niidome et al. have found correlation between the helical character of peptides 
and DNA transfection(126). Moreover, Niidome et al. results indicated that 
peptides with continuous large hydrophobic region could form stable particles 




1.5.2.2. Attachment of inert polymers to enhance  
the circulation time of the peptide  
To tackle the stability problem of the CPP-nucleic acid particle in the blood 
attachment of inert polymers to CPP has been utilized to reduce the protein 
adsorption onto the surface of CPP-NA particle. The most commonly incorpo-
rated polymer to decrease opsonization and increase CPP-NA particles 
resistance against hydrolytic enzyme is hydrophilic PEG (polyethylene glycol). 
PEG can be used to cover the surface of the nanoparticle to enhance water 
solubility of the particle and to suppress non-specific interaction with blood 
components for a reduced blood clearance. First illustrations of the potential of 
surface pegylation of nanoparticles arose in early 1990s when different research 
groups reported that pegylation of liposomes enhanced blood circulation times 
of liposomes(129,130). Thereafter, Grief and colleagues showed the similar 
results with pegylated poly(lactic-co-glycolic acid) nanospheres(131). Although 
pegylation is a great strategy to increase half-life of particles it can inhibit 
binding with target molecules thereby reducing the efficacy of the delivery 
(known as PEG dilemma)(132). To overcome this problem various groups have 
utilized cleavable linkers which when cleaved release the sterically shielding 
PEG from nanoparticle. Several cleavage conditions can be applied to design 
reducible(133), pH-dependent(134–136) or protease-cleavable(137,138) linkers. 
Pegylated CPPs have shown to increase circulation time and tumor tissue 
transfection(116) and incorporated into formation of liposome-based nano-
particle to further enhance the drug delivery(139–141). 
 
 
1.5.2.3. Conjugation of the CPP with shielding sequences  
to enhance the transfection specificity 
Several shielding moieties have been conjugated to CPPs to increase the 
specificity of the transfection. Shielding anionic sequences (usually sequences 
containing Glu amino acids) have been conjugated to CPPs to create activatable 
CPP (aCPPs)(142). aCPP concept was first introduced by Tsien and 
colleagues(142) and they used shielding properties of Glutamate sequences to 
target specifically tumor tissue (shown in Figure 5). Tumor targeting with aCPP 
takes advantage of the diseased tissue microenvironment (such as acidity, 
reducing environment) to dissociate shielding moiety from CPP once the target 
tissue has been reached. Besides addition of shielding anionic sequences other 
masking strategies have been applied such as pH sensitive oligopeptides. 
Cationic CPP MAP fusion with pH sensitive His-Glu oligopeptide have been 
synthesized to mask cell-penetrating moiety at neutral pH(143). After exposure 
to mildly acidic pH this pH-sensitive masking moiety significantly enhanced the 




Figure 5. The specificity of the CPP towards specific tissue or cells can be enhanced 
through the incorporation of shielding moieties (modified figure from Jiang et al. 2004 
(142), Copyright (2004) National Academy of Sciences, U.S.A.). 
 
 
1.5.2.4. Conjugation of the CPP with targeting moieties to enhance 
the transfection specificity and efficacy 
In addition to shielding strategy various targeting moieties are also used to 
enhance specificity of the transfection. Various antibodies(144,145), homing 
peptides(146,147) and targeting sequences of organells(148) have been utilized. 
One of the most broadly used targeting moieties with CPPs are so called 
homing sequences which take advance of target tissue distinct microenviron-
ment and unique expression pattern of membrane receptors to target specific 
cells. For example, compared to the normal tissue environment, the tumor 
microenvironment displays stromal cell abnormalities, abnormal protein 
expression, acidosis, and hypoxia(149). These differences can be utilized for the 
selective delivery of therapeutics. With the advancement in the phage-displayed 
peptide library screening technique, various homing peptides have been identi-
fied that have tumor homing capacity(150). These peptides can specifically bind 
to various receptors that are uniquely expressed or over-expressed in tumor 
tissues. Compared with antibodies, homing peptides are much smaller in size 
and more efficient in tissue penetration and relatively easy to synthesize at 
much lower cost(149). Thus these homing peptides can be can be integrated into 
specifically tumor targeting formulation of particles(146,147,151,152). Despite 
broad utilization of homing peptides their in vivo application is still hindered 





1.5.2.5. Incorporation of magnetic iron oxide for more efficient 
targeting of CPP particles 
Although antibodies for receptors (as antigens) expressed in the target tissue 
have been used in targeting tumors their bulk size hinders their penetration into 
solid tumors(155). Also, reengineering of antibodies is usually needed to 
minimize possible immunogenic side-effects(155). In addition to antibodies, 
various small molecule ligands have been widely utilized for targeted delivery, 
but they lack efficient tumor targeting specificity required for in vivo gene 
therapy(149,156).  
To enhance specific accumulation of nanoparticles into the target tissue one 
possibility is to use magnetic targeting. Magnetic targeting utilizes para-
magnetic particles to guide their accumulation into the target tissue with local 
strong magnetic fields(157). These magnetic particles exhibit superparamag-
netism properties which mean that on application of an external magnetic field, 
they become magnetized and when magnetic field is removed they no longer 
exhibit any residual magnetic interaction. These magnetic nanoparticles can 
facilitate the transport of biomolecules to their target site in the body under the 
influence of an applied magnet field(157). Magnetic nanoparticles have been 
used since 1970s when Freeman et al first introduced the concept of using 
magnetism in medical and biological sciences(158). In biomedical application, 
the most commonly used magnetic particles are iron oxides magnetite (Fe2O4) 
and maghemite (γ-Fe2O3) with a size ranging between 10 nm and 100 nm in 
diameter(157). Iron oxide particles are mostly used because of their relative 
ease of synthesis, biocompatibility and approval of Food and Drug Administ-
ration compare to other magnetic particles such as cobalt based particles 
(157,159).  
The current research on iron oxide particles aims to use these particles as 
diagnostic agents in magnetic resonance imaging as well as for drug delivery 
vehicles(157). For biological utilization magnetic particles must be coated to 
enhance their colloidal stability, circulation time in blood, dispersity in aqueous 
solution and for achieving functional surfaces(157,159). Magnetic Fe2O4 par-
ticles have been coated and combined with various molecules such as lipids(160), 
ethyl cellulose(161), poly(D,L-lactide-co-glycolide)(162) and chitosan(163) to 




2. AIMS OF THE STUDY 
The main aim of this thesis was to design more efficient and safer formulations 
of CPP/nucleic acid particles for the systemic in vivo delivery of nucleic acids. 
For that the peptide vector complexes with nucleic acids were investigated to 
improve the formulation method of particles to enhance the gene delivery in 
vivo.  
The specific goals of this study are as follows: 
Paper I, the aim of this research was to rationally design an improved novel 
peptide for efficient in vivo gene delivery using knowledge from internalization 
studies of different CPPs. 
Paper II, the aim of this study was to develop a new formulation approach to 
prepare uniformly sized nanoparticles for their further enhanced utilization in 
vivo.  
Paper III, the aim of this research was to reduce the non-specific transfection 
of the peptide vector by incorporation of magnetic particles to enhance the 
peptide vector efficacy and specificity. 
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3. MATERIALS AND METHODS 
3.1. Synthesis of peptides with solid phase  
peptide synthesis method 
All synthesized peptides are described in Table 1. Peptides were synthesized in 
stepwise manner at 0.1 mmol scale on an automated peptide synthesizer using 
Fmoc (fluorenylmethyloxycarbonyl) solid-phase peptide synthesis strategy 
(SPPS) (164) with Rink-amide MBHA (methylbenzylhydrylamine) resin as 
solid phase to obtain C-terminally amidated peptides. Fmoc SPPS was preferred 
over Boc based SPPS because it abled us to use milder deprotection and final 
cleavage (TFA acid) and monitoring of the deprotection rate via UV detection 
compared to harsh conditions (HF acid) needed for Boc SPPS.  
 
Table 2. Synthesized peptides.  
Peptide Sequence Ref 
NF1 Stearyl-AGY(PO3)LLGKTNLKALAALAKKIL-NH2 (69) 
NF2 Stearyl-AGYLLGKT(PO3)NLKALAALAKKIL-NH2 (69) 
NF16 Stearyl-AGELLGKTNLKALAALAKKIL-NH2 (72) 
NF17 Stearyl-AGYLLGKENLKALAALAKKIL-NH2 (72) 
NF18 (Stearyl-AGELLG)δ-OINLKALAALAKKIL-NH2  (72) 
NF19 (Stearyl-AGYLLG)δ-OENLKALAALAKKIL-NH2  (72) 
NF51 (Stearyl-AGYLLG)δ-OINLKALAALAKKIL-NH2  (70) 
NF54 (Stearyl-AGYLLG)δ-OINLKALAALAAKIL-NH2  (72) 
NF55 (Stearyl-AGYLLG)δ-OINLKALAALAKAIL-NH2  (72) 
NF551 (Stearyl-AGYLLG)δ-OINLKAK(C*)AALAKAIL-NH2  (72) 
NF552 (Stearyl-AGYLLG)δ-OINLKALAALAKAILC*-NH2  (72) 
PF14 Stearyl- AGYLLGKLLOOLAAAALOOLL-NH2 (64) 
PF220 Stearyl- KWLKLWFLKLLKKFL-NH2  (165) 
PF221 Stearyl- FLKLLKKFLFLKLLKKFL-NH2  (165) 
PF222 Stearyl- WLRLLWKKWFLKL-NH2  (165) 
PF223 Stearyl- KWLKLWAGYLLGKINL-NH2  (165) 
PF224 Stearyl- WKKWINLKALINLKAL-NH2  (165) 
* PEG2000-Cys is conjugated via disulfide bond 
 
In Fmoc solid-phase peptide synthesis, the peptide chain is created stepwise 
using amino acids protected either Fmoc or t-Boc (tert-butyloxycarbonyl) 
groups. In paper I for the synthesis of NF51, NF54 and NF55 t-Boc monomers 
Boc-l-Orn(Fmoc)-OH were used. For synthesis of phosphorylated peptides 
phosphothreonine Fmoc- Thr(PO(OBzl)OH)–OH (Fluka, Germany) and 
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phosphotyrosine Fmoc-Tyr(PO(OBzl)OH)–OH (Merck, Germany) monomers 
were used and the coupling was carried out manually. The final cleavage was 
performed using standard protocol. Peptides were purified by reversed-phase 
HPLC using C4 column (Phenomenex Jupiter C4, 5 μm, 300 A, 250 × 10 mm) 
using a gradient of 20–80% acetonitrile/water containing 0.1% TFA. The 
identity of peptides was analyzed by matrix-assisted laser desorption ionization 
time-of flight (MALDI-TOF) mass-spectrometry (The Voyager-DE™ PRO Bio-
spectrometry™ System) in positive linear mode using α-cyano-4-hydro-
xycinnamic acid as matrix (Sigma–Aldrich). 
 
 
3.2. Formulation strategies of nanoparticles  
applied in the thesis 
In this thesis, we use non-covalent complex formation where we condense 
negatively charged nucleic acids with positive-charge bearing peptide mainly 
via electrostatic interaction. This kind of nanoparticle assembly is widely used 
for transfecting cells with oligonucleotides, siRNA, SCO and plasmid DNA 
with various poly-cationic molecules such as poly-lysine, chitosan, cationic 
lipids and polyethyleneimine. 
To assemble peptide-pDNA complexes with different charge ratios (CR) the 
negative charges of DNA phosphate, the positive charges of the peptide amino 
groups and the negative charges of the phosphoryl group or amino acid side 
chain group of peptides were considered. This means that the peptide/nucleic 
acid charge ratio is the proportion of moles of positively charged amino acid 
groups in the CPP to those of phosphate ones in the nucleic acid. The CR 
corresponds to more extensively used nitrogen to phosphate ratio N/P. 
 
 
3.2.1. Formulation 1 method for preparation  
of nanoparticles for in vitro studies 
Nanoparticles are prepared by mixing pDNA with the peptide in MQ water. 
Thereafter nanoparticles are incubated for 30 min at room temperature to 
assemble complexes before starting transfection experiments. In this thesis the 
term formulation 1 is used to indicate nanoparticle formulation protocol for the 
cell culture experiments. As transfection efficacy is highly dependent on the 
used CRs, cell type, temperature, and other conditions of the experiment we 
have optimized this so called in vitro formulation method for the transfection of 
various mammalian cell lines in our previous studies. The optimal amount of 
plasmid for generally transfected mammalian cells is 0.5 µg per well of 24-well 
plate containing 50 000 seeded cells which have been allowed to grow at 
confluency of 70–80%. Standardly charge ratios between 1 to 5 is first used to 
screen and find the best formulation charge ratio to continue further with more 
extensive studies.  
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3.2.2. Formulation 2 method for preparation  
of nanoparticles for in vivo studies 
In this thesis the term formulation 2 indicates the protocol for assembling 
particles for the systemic administration in vivo. In the previous studies we have 
optimized the formulation method of particles to find the charge ratios which 
are safe and effective for the plasmid delivery via intravenous administration. 
To achieve efficient systemic delivery of pDNA in vivo 10 times higher dose of 
nanoparticle is needed compared to formulation 1 described earlier. Standardly 
20 μg of pDNA is mixed with peptide at charge ratio 2 to 4 to yield dose 
administered per one animal (1 mg/kg). Thereafter 30 min incubation at room 
temperature is used to formulate nanoparticles. After complexation glucose is 
added to achieve an isotonic injection solution (5%).  
 
 
3.2.3. Filtration of complexes 
For the removal of aggregated particles and to create more homogenous size 
distribution of nanoparticles, complexes were formulated as described above 
(formulation 2) and then filtered through 100 nm or 200 nm pore-sized 
polypropylene filters (Pall, Acrodisc, USA). The filter sizes were chosen based 
on the aim to prepare particles between 100 to 200 nm which are suitable for in 
vivo administration. To quantify the recovery of plasmid and peptide after 
filtration, PicoGreen (Quant-iT™ PicoGreen®, ThermoFisher Scientific) and 
the Lowry based protein detection method (DC protein determination kit, Bio-
Rad Laboratories, Inc., USA) were used. For in vitro studies, we diluted 
complexes ten-fold, thereby achieving a concentration equal to formulation 1 
which are standardly used protocol for the cell culture experiments in our lab. 
 
 
3.2.4. Cryo-concentrated formulation of nanoparticles 
To enable better control over properties of formulated nanoparticles and to 
further improve transfection efficacy we aimed to prepare particles with more 
uniform size. For that we developed a cryo-concentrated formulation protocol. 
To formulate the cryo-concentrated complexes (CCC), a combination of 
formulation 1 and 2 was used. 20 μg of plasmid was mixed with the peptide at 
CR4 according to the formulation 1 (final peptide concentration 40 μM in a 
total volume of 2 ml of MQ water). After 30 min of incubation, glucose was 
added according to the formulation 2 (to achieve an isotonic injection solution 
(5%)), and thereafter, the formulated complexes were lyophilized. Prior to use 
in transfection experiments, the complexes were reconstituted in appropriate 




3.2.5. Iron oxide incorporation into PF/nucleic acid particles 
In the paper III we selected PF14-derived peptides because the parent peptide 
PF14 and its complexes with pDNA, SCO and siRNA have been thoroughly 
studied both in vitro and in vivo. Utilized PF14 analogues were first designed 
and described by Dowaidar et al. with a statistical method based on regression 
data analysis quantitative structure–activity relationships (QSAR)(165). From 
this study the most efficient PF peptides for nucleic acid transfection were 
selected. Iron oxide nanoparticles were incorporated into PF/nucleic acid 
nanoparticles to increase the selectivity and efficiency of gene therapy.  
Iron oxide/PF/pDNA particles were prepared by mixing a suspension of iron 
oxide particles with pDNA and thereafter PF peptide was added to reach charge 
ratio 5 between peptide and pDNA. Complexes were then allowed to assemble 
through incubation at room temperature for 2h. 
Iron oxide/PF/SCO particles were formulated at PF and SCO molar ratio 10. 
Again, first nucleic acid (at final concentration 10 µM) was added to iron oxide 
solution and thereafter PF peptide was introduced. To assemble particles 2h 
incubation was used. 
Iron oxide/PF/siRNA complexes were formulated at PF and siRNA molar 
ratio 20. First siRNA (at final concentration 25 µM or 50 µM) was mixed with 
iron oxide solution and thereafter PF peptide was added. Complexes were 
incubated 2h at room temperature. 
 
 
3.3. Characterization of peptide nanoparticles 
3.3.1. Computational methods 
To investigate the impact of amino acid sequence alterations to the secondary 
structure of new peptide analogues computational analysis was used. Structures 
of individual peptides were built or adapted and minimized in implicit solvent 
using chemical simulation software Schrödinger Software Package version 
2015. For the resulting structures, the molecular surfaces, molecular electrostatic 
potentials, and hydrophilic/hydrophobic maps were calculated with Maestro. 
Maestro is the graphical user interface for Schrödinger’s computational programs. 
Primary sequences of standard amino acids were used to calculate the potential 
for aggregation using statistical mechanics in Tango. Tango, is an algorithm for 
identifying β-sheet aggregation propensity and can be used to predict which 





3.3.2. Circular dichroism spectroscopy 
Structural properties of peptide play a major role in the cellular delivery efficacy 
of peptide-based nanoparticles. In this thesis we used Circular dichroism (CD) 
spectroscopy to study the effect of alterations in peptide sequence on secondary 
structure of peptide. CD spectroscopy is wildly used method for analyzing the 
conformation of proteins and peptides in solution. CD detects wavelength-
dependent differences in the absorption of right and left circularly polarized 
light by optically active molecules such as peptides. The CD spectrum of 
unordered peptides is described by a single band below 200 nm, at the same 
time alpha-helical structures usually present two negative bands at 208 and 
222 nm along with one positive band at 192 nm; beta-sheet structures typically 
show a negative band at 217 nm and a positive band at 195 nm(167).  
Estimation of α helix and β strand content of the peptides, from their circular 
dichroism spectra, was calculated using the K2D2 algorithm. 
 
 
3.3.3. Dynamic light spectroscopy 
As size and surface charge of the nanoparticles can determine the intracellular 
fate, toxicity, and bio-distribution of particles after administration it is essential 
to study these physicochemical properties. One of the most commonly used 
techniques for the analysis of nanoparticles and protein aggregates is dynamic 
light scattering (DLS)(168). DLS measures the rate at which the intensity of the 
scattered light fluctuates due to Brownian motion and correlates this to the size 
of the particles. The DLS obtains a hydrodynamic diameter based on the 
diffusion of the particles and the hydrodynamic diameter indicates the effective 
diameter of a particle in a liquid. The mean hydrodynamic mean diameter of the 
nanocomplexes was determined by dynamic light scattering studies using a 
Zetasizer Nano ZS apparatus (Malvern Instruments, United Kingdom). All 
results were based on three or four measurements from two independent 
samples. All data were converted to relative by intensity or volume plots from 
which the mean hydrodynamic diameters were derived. 
 
 
3.3.4. Transmission Electron Microscopy  
For the morphological characterization of complexes, a Transmission Electron 
Microscopy (TEM) analysis was performed. TEM is a characterization method 
for imaging nanoparticles to obtain quantitative measures of particle size (with-
out the hydration layer), size distribution and morphology. TEM visualizes the 
transmission of a focused beam of electrons through a sample, forming an 
image similarly to a light microscope, but because electrons are used rather than 
light to visualize the sample, TEM imaging has significantly higher resolution 
compared to light microscope. 
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3.3.5. Energy-dispersive X-ray spectroscopy 
Energy Dispersive X-ray Spectroscopy (EDS) was used in this thesis to map the 
elemental composition of nanoparticles. EDS is a chemical analysis method that 
can be used with the two major electron beam based techniques of Scanning 
Electron Microscopy and Transmission Electron Microscopy. EDS analysis can 
be utilized to determine the elemental composition of individual points, line 
scans or to map out the lateral distribution of elements from the imaged area. 
 
 
3.3.6. Characterization of stability of particles 
3.3.6.1. Gel retardation assay 
The gel retardation assay is widely used method to study the peptide and nucleic 
acid interaction and nanoparticle formulation. In this assay electrophoresis is 
used to analyze the complex formation between positively charged peptide and 
negatively charged nucleic acids. The rationale behind this assay is that electro-
phoretic mobility of negatively charged DNA, complexed with positive CPPs, 
should decreases gradually on the agarose gel with increasing charge ratio. The 
decreased mobility shift of nucleic acids indicates stronger interaction with 




3.3.6.2. Competitive displacement assay 
Formulation of stable and compact nanoparticles that would not dissociate after 
the exposure to serum is essential for the efficient transfection. The high sta-
bility of particles is required to deliver nanoparticles into the cells in serum and 
thereafter intracellularly into the nucleus. At the same time DNA needs to be 
released inside the cell to be expressed. Hence, it is necessary to form nano-
particles that are neither too stable nor labile. We therefore investigated plasmid 
DNA condensation by peptides at different charge ratios and dissociation of the 
complexes by heparin competitive displacement assay. To study the dissocia-
tion of peptide and DNA particles many polyanions have been used to com-
petitively displace DNA from complexes. The most extensively used polyanion 
is heparin sulfate. Heparin sulfate has high negative charge density and can 
displace nucleic acids from loosely packed nanoparticles. Heparin sulfate has 
previously been found to mediate DNA release from polyelectrolytes as well as 
cationic liposomes(169). The displacement of DNA in labile and loosely packed 
particles by heparin salt is grater compare to more tightly packed particles. In 
heparin displacement assay peptide/pDNA complexes were mixed with 
fluorescent nucleic acid stain PicoGreen reagent (Invitrogen) for quantitating 
double-stranded DNA. Thereafter heparin sulfate (Sigma-Aldrich) was added to 
the complex solution and then incubated and analyzed. In each experiment, 
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naked DNA stained with PicoGreen was used to normalize the PicoGreen fluo-
rescence signal detected from the complexes. After this fluorescence was 




3.3.6.3. Resistance of complexes to enzymatic degradation 
The resistance of particles to protease degradation is critical to their use in drug 
delivery in vivo. Resistance to protease digestion might indicate the longer half-
life of nucleic acid and therefore greater bioactivity in protease-rich environ-
ment like in blood serum. The aim of this assay was to estimate how tightly are 
nanoparticles packed and how accessible is peptide in complex for protease 
degradation. Proteinase K treatment was carried out to evaluate the resistance of 
the pre-formed NF/DNA complexes to enzymatic degradation of CPP by 
proteinases. Proteinase K is proteolytic enzyme with broad specificity purified 
from the fungus Tritirachium album.(170)  
 
 
3.3.7. Screening of bioactivity of particles 
In this thesis the term bioactivity of peptide/nucleic acid particles indicates the 




3.3.7.1. Cell culture 
Utilization of different cell lines is essential for better understanding of uptake 
of peptide-based nanoparticles as internalization mechanism of particles is 
dependent on cell type. We used multiple adherent cell lines which are com-
monly used to study transfection efficacy. Cell types used in this thesis are 
described in Table 2. 
In paper I, epidermal primary keratinocytes were additionally used to further 
investigate efficacy of new NF analogues in primary cell culture.  
In paper III, HeLa pLuc 705 cell line was utilized to study the transfection 
efficiency of PF/SCO particles in the widely used assay for splice correction. 
HeLa pLuc 705 cells are extensively utilized as a functional assay system to 
study the vector efficacy to deliver antisense oligonucleotides into cells. HeLa 
pLuc 705 cells are HeLa cells stably transfected with recombinant plasmid 
(pLuc/705) carrying the luciferase gene interrupted by a mutated human  
β-globin intron 2 (IVS2-705)(171). This mutation causes aberrant splicing of 
luciferase pre-mRNA in HeLa pLuc/705 cells. After the delivery of antisense 
oligonucleotide and thereby the correction of splicing, the functional luciferase 
is produced, and luminescence signal can be measured to examine the efficacy 
of the transfection. 
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Table 3. Cells used in this thesis. 
Cells Cell type Paper 
HeLa Epithelial cervix adenocarcinoma I, III 
HeLa pLuc 705 Epithelial cervix adenocarcinoma, stably transfected with 
recombinant plasmid (pLuc/705) 
III 
CHO Epithelial-like ovary derived cells I, II 
U87-MG Epithelial glioblastoma astrocytoma cell line I, III 
U87-MG-luc Epithelial glioblastoma astrocytoma cell line, stably 
expressing luciferase 
III 
Neuro2A Neuroblastoma neuroblast neuronal and amoeboid stem 
cells 
I 
HT-1080 Epithelial fibrosarcoma I 
Keratinocytes Human epidermal primary keratinocytes I 
 
 
3.3.7.2. Transfection studies 
In this thesis CPP transfection efficacy was evaluated using plasmid DNA, SCO 
and siRNAs. We utilized multiple reporter systems for the screening of the 
efficiency of the peptide to facilitate the nucleic acid transport into cells. 
In all three papers, pDNA transfection studies were investigated using  
p-CMV-Luc2 plasmid which express firefly luciferase. This is broadly utilized 
reporter system which is sensitive, robust, and easy to measure. p-CMV-Luc2 is 
10kb-sized reporter plasmid which codes firefly (Photinus pyralis) luciferase 
that has been optimized for monitoring transcriptional activity in eukaryotic 
cells. After pDNA transfection cell or tissue lysate is mixed with luciferin and 
thereafter expressed luciferase activity is measured. The quantified lumine-
scence signal correlates with transfection efficacy. 
In paper I, we also transfected cells with two additional plasmids, p-EGFP 
plasmid encoding GFP and p-7SK-shRRM2 plasmid. p-EGFP plasmid was used 
to estimate the proportion of transfected population of cells using FACS by 
measuring the fluorescence signal from transfection-positive cells. p-7SK-
shRRM2 plasmid was used to study gene modification in biologically relevant 
context, outside reporter system. This plasmid encodes short hairpin RRM2 and 
we aimed to down-regulate ribonucleotide reductase subunit M2 (RRM2) gene. 
Down-regulation of RRM2 gene have been shown to significantly reduce the 
cell growth and adhesion. Therefore, we treated cells with NF/ p-7SK-shRRM2 
nanoparticles and determined population of viable cells with flow cytometry 
from a scatter plot. 
In paper III, we investigated CPP efficacy to deliver also splice-correcting 
oligonucleotides into cells. Treatment of the cells with a SCO targeted to the 
aberrant splice site restores luciferase expression and quantified luminescence 
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signal correlates with efficacy of SCO delivery. We used SCO to correct 
aberrant splicing of luciferase pre-mRNA in HeLa pLuc/705 cells.  
In paper III, we also used stably expressing luciferase U87-MG-luc cell line 
to deliver siRNA that targets mRNA of luciferase and causes degradation of the 
luciferase mRNA that leads to a decrease in the signal of luminescence. 
 
 
3.3.7.3. Toxicity evaluation of particles 
The CytoTox-Glo™ Assay is a luminescent cytotoxicity assay that measures the 
relative number of dead cells in cell populations. The assay is based on detec-
tion of differential ubiquitous proteolytic activities associated with intact viable 
cells and cells that have lost membrane integrity (172). The method uses a 
luminogenic peptide substrate (alanyl-alanylphenylalanyl-aminoluciferin) which 
cannot cross intact membranes to measure protease activity which is released 
from cells that have lost membrane integrity. Therefore, luminescent signal can 
be used to calculate dead cells. 
We also used WST-1 assay which uses tetrazolium salt WST-1 (2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H 
tetrazolium, monosodium salt) which is enzymatically cleaved to formazan by 
cellular mitochondrial dehydrogenases in viable cells. The formazan dye 
produced from WST-1 by viable cells can be quantified by measuring the 
absorbance of the dye at 440 nm. 
For in vivo toxicity evaluation of nanoparticles, we used frequently used 
liver function blood test. We analyzed two liver enzymes alanine transaminase 
(ALT) and aspartate transaminase (AST) for detecting any inflammation or 
damage to cells in the liver after administration of peptide-based nanoparticles. 
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4. RESULTS AND DISCUSSION 
4.1. Design of the effective peptide vector  
for systemic in vivo transfection 
Progress in genomic sequencing have given us opportunity to regulate almost 
any gene expression in transcriptome through exogenous therapeutic nucleic 
acids. The main drawback of that kind of gene manipulation is poor cellular 
uptake of nucleic acids, especially in systemic administration in vivo. There-
fore, the main challenge in creating effective gene-based therapies is the 
development of selective and safe delivery vectors. 
 
 
Figure 6. Illustration of the design of novel analogues of NFs. 
 
In the Paper I, previous knowledge from internalization studies and physio-
chemical properties of different analogues of NickFects (NF) was utilized to 
rationally design new NF peptides for in vivo use. We have previously designed 
two efficient NF analogues, both displaying similar efficacy despite having 
different structure and uptake mechanism(69,70). NF51 formulated stronger 
complexes with pDNA and delivered plasmid into cells via macropinocytosis 
while NF1 nanoparticles were less stable and entered cells through macropino-
cytosis and clathrin- or caveolae-mediated endocytosis(71). Although showing 
great transfection in cell culture, both peptides lacked in vivo delivery. We 
therefore hypothesized that we could combine modifications made to these 
peptides to create the vector more suitable for in vivo application. The graphic 





Figure 7. α-helical wheel projectors shown for NF51 and its analogues, indicating 
rationality of the location of amino acid replacement. 
 
We first investigated if phosphorylation itself or the negative charge from 
phosphorylation is required for NF1 and NF2 transfection. As addition of a 
phosphoryl group has been shown to increase the transfection(173) we first 
studied the importance of phosphorylation and charge location within NF1 and 
NF2 sequence by synthesis of NF16 and NF17. In NF16 and NF17 phospho-
rylated amino acids were replaced with Glu which bears negative charge at 
physiological pH. After verifying that charge, not phosphorylation is essential 
for the transfection; similar alterations were introduced into NF51 sequence 
(NF18, NF19). These modifications in NF51 sequence however decreased 
transfection efficacy and uptake studies revealed that C-terminus modifications 
were less deleterious than alterations in the N-terminus sequence. Since insertion 
of Glu into N-terminus sequence decreased transfection, further modifications 
were made into C-terminus. After seeing no advantage by insertion of negative 
charge we continued to reduce the charge by replacing the positively charged 
lysines with alanines. These modifications were introduced again into C-ter-
minus sequence and therefore two Lys at C-terminus in NF51 sequence, 18th 
and 19th, were replaced with Ala (α-helical wheel projectors of designed 
peptides are shown in Figure 7). Interestingly, only one analogue, NF55 showed 
improved transfection. Further CD spectroscopy studies revealed that this 
higher delivery efficacy might arise because of NF55 increased α-helical 
secondary structure compared to other NF peptides (in the Paper I, Figure 2). 
Indeed, the importance of helicity in TP10 and other CPPs for transfection has 
been shown previously by Song et al.(174) and Niidome et al. (126).  
Next, after we had screened and selected the best peptide for gene delivery, 
we characterized NF55/pDNA particles and found that NF55 condenses pDNA 
into stable nanoparticles that are more resistant to protease degradation than 
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parental peptide NF51 nanoparticles (in the Paper I, Table 2). We propose that 
this can be because NF55 is more hydrophobic (in the Paper I, Table 2) than 
NF51 and hydrophobicity has been shown to increase peptide-DNA binding. 
The development of the more protease-resistant particles is essential, especially 
for the systemic in vivo administration as the half-life of the particle in blood 
stream greatly determines the transfection efficacy of the nanoparticle. Before 
continuing in vivo, we estimated the NF55 ability to escape from endosomes as 
entrapment of particles into endosomes has been shown to hinder the trans-
fection. Endosomal escape studies revealed that in contrast with other NickFects, 
NF55 is not significantly hindered by endosomal entrapment (in the Paper I, 
Figure 3B).  
After verifying that NF55 is highly efficient CPP in vitro we aimed to 
investigate its utilization in vivo (Figure 8). When delivering pDNA with NF55 
systemically, we noticed like often reported with cationic particles, significantly 
high gene induction in lungs and liver. Surprisingly, we observed over 22-fold 
higher gene induction in cerebellum and 7-fold higher reporter gene expression 
in the rest of the brain tissue after NF55/pDNA treatment compared to naked 
pDNA treatment. Reporter gene induction was significantly higher in NF55 
treatment compared to parental peptide NF51 and naked pDNA treatment. 
Furthermore, NF55/pDNA particles demonstrated comparable transfection with 
the best commercial in vivo transfection reagents in main organs (especially in 
lung tissue) and 5-fold greater bioactivity in cerebellum. This demonstrate the 
potential of NF55 to be an effective gene delivery vector and as a safer 
alternative to currently used transfection reagents which although very efficient, 
might cause side-effects. 
After we have verified NF55 ability to transfect various tissues in vivo we 
aimed to deliver pDNA specifically into tumor and reduce lung and liver 
transfection. Because we detected high luminescence signal from cerebellum 
and brain after NF55 treatment we were interested to investigate it further and 
studied the transfection with intracranial glioblastoma model. Therefore, we 
compared NF55 and the parental-peptide NF51 efficacy to transfect intracranial 
tumor tissue. Interestingly, we detected 45-fold higher reporter gene expression 
in tumor-containing striatum compare to naked pDNA treated mice (in the 
Paper I, Figure 4B). Unfortunately, despite this high accumulation of NF55 
particles into tumor tissue the similar gene expression was also observed in 
unaffected brain regions (in the Paper I, Figure 4B). Moreover, highest trans-
fection was detected again in lungs and liver. This indicated the need to 





Figure 8. The novel analogue NF55 significantly enhances the transfection in balb/c 
mice at CR4. 20 μg pDNA was used to form nanoparticles with different delivery 
vectors except TurboFect termed with *, where 50 μg pDNA was used. The data is from 
at least three representative experiments performed in triplicate, presented as mean ± 
SEM, *P < 0.05; **P < 0.01 (Student t-test, two-tailed distribution, two-sample unequal 
variance. 
 
Therefore, to increase the delivery of NF55/pDNA particles into the tumor tissue 
and to decrease the non-specific lung and liver accumulation we conjugated 
PEG polymer to NF55. As the helicity of the peptide is important for the 
transfection, the pegylation site in the peptide was selected and screened to 
maximize α-helicity of the NF55 (in the Paper I, Table S2). Various pegylated 
NF55 peptides were designed to utilize PEG shielding ability to decrease 
accumulation into lungs and liver and increase the transfection into tumor. To 
screen for the best formulation, we then moved away from intracranial model 
and continued studies using subcutaneous tumor. Two pegylated NF55 ana-
logues NF551 and NF552 demonstrated the highest percentage of α-helix 
secondary structure and were chosen to formulate nanoparticles with different 
ratios with NF55. We aimed to optimize and find the optimal ratio of NF55 and 
the pegylated variant of NF55 (NF551 or NF552) which would form stable 
complexes with DNA and reduce the non-specific accumulation, but at the same 
time do not decrease the transfection into the tumor tissue. The latter pheno-
menon is known as PEG dilemma and it has been observed that incorporation of 
high concentration of PEG could significantly decrease the transfection. The 
most effective formulation was with 20% NF552/80% NF55/pDNA as it 
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increased tumor accumulation over three times and reduced the lung trans-
fection over 38-fold compared to NF55/pDNA treatment alone. These results 
indicate that NF55/pDNA particles can be optimized for more efficient tumor 
accumulation through the incorporation of pegylated peptides. 
Finally, we investigated the possibility to produce solid formulation of 
NF55/pDNA particles. This is essential as solid formulations are more stable 
during storage and transportation and remain the most extensively used pharma-
ceutical formulation currently utilized. The lyophilized pre-formed NF55/pDNA 
complexes did not conglomerated after lyophilization, and their size and shape 
were similar to that of non-lyophilized particles. Moreover, the storage at room 
temperature for seven days did not affect the bioactivity of these lyophilized 
particles. These results demonstrate that NF55/pDNA particles can be prepared 
and stored as a solid formulation without sacrificing its bioactivity.  
Taken together, these results demonstrate that we have designed very 
efficient transfection reagent for in vivo utilization and illustrated the potential 
of NF55 to be modified for further targeting gene delivery.  
 
 
4.2. Formulation of stable and homogenous nanoparticles 
for the efficient gene delivery in vivo 
In clinical settings, it is necessary for pharmaceutical to possess strictly cont-
rolled and defined molecular composition and structural characteristics. It is 
essential as physicochemical parameters, including size and size distribution 
influence the biodistribution and toxicity of nanoparticles. Therefore, in the 
Paper II we continued to further investigate the physicochemical properties of 
the previously designed and formulated NF55/pDNA particles and to develop a 
new formulation approach to prepare NF55/DNA nanoparticles with more 
homogenous size distribution. The main aim was to prepare particles with more 
controlled size and size distribution for more safe and efficient systemic in vivo 
gene delivery. The graphic scheme of different formulation methods applied in 
the Paper II can be seen in Figure 9. 
We have previously shown that our CPPs condense pDNA into approxi-
mately 100 nm sized stable homogenously distributed nanoparticles, but during 
characterization of NF55/pDNA particles, we discovered that in addition to 
major fraction of 100-nm sized particles a small fraction of these particles 
aggregated and formed larger conglomerates (Figure 10, formulation 1). This 
conglomeration was surprising and to investigate this further we used DLS to 
compare particles prepared using two formulation protocols which differ in used 
concentration of nanoparticles. We compared formulation 1 protocol which is our 
usual complex formulation method for transfecting the cell culture to formu-
lation 2 method.  
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Figure 9. Graphic scheme of different formulation methods applied in the Paper II. This 
includes formulation 1 which is used in cell culture studies, formulation 2 which is 
prepared for the systemic in vivo gene delivery, formulation method of filtrated 
formulation 2, and the modified formulation strategy to produce cryo-concentrated 
complexes (CCC). The darker blue color indicates the higher concentration of particles. 
 
In formulation 2 protocol we use ten times higher concentration of particles as 
higher concentration of particles is needed for the efficient systemic in vivo 
transfection (for example the concentration of peptide is 400 µM compare to 
40 µM used in formulation 1). DLS measurements with formulation 1 revealed 
mainly one distinctive population of NF55/pDNA nanoparticles with an average 
size of 100 nm. On the other hand, when we repeated the measurements at 
higher concentration of particles we observed significantly more agglomerated 
particles (Figure 10, formulation 2). Particles formulated at higher concentration 
(formulation 2) displayed very heterogeneous size distribution and only 1/3 of 
population of nanoparticles were approximately in the desired size range of 
100 nm for the in vivo application (Figure 10). This demonstrated the need for 
the development of more suitable formulation method of particles to prepare 
nanoparticles with controlled size and with more homogenous size distribution. 
To reduce heterogeneous size distribution of NF55/pDNA particles we 
utilized filtration method (Figure 9). In our experiments both, DLS and TEM 
studies also confirmed that filtration successfully removed large conglomerates 
from formulation 2 and similarly to formulation 1, only one distinctive popu-
lation of about 125-nm diameter nanoparticles were obtained. Moreover, 
filtration also lowered significantly polydispersity index compared to 
formulation 2. Despite successful elimination of aggregates bioactivity in cell 
culture was reduced over 1000-fold and transfection in vivo also diminished 
after nanoparticle filtration (Figure 12). These results demonstrate that although 
filtration of complexes yield homogenous size distribution of particles the 






Figure 10. NF55/DNA particles formed at the higher concentration needed for the 
systemic in vivo gene delivery (formulation 2) tend to aggregate and form larger 
conglomerates compare to formulation 1 which is used in the cell culture studies. DLS 
measurements with formulation 1 (green line, peptide concentrations 40 μM) and 
formulation 2 (dashed red line, peptide concentrations 400 μM). 
 
As filtration did not gave us the desired outcome we investigated alternative 
method to produce more uniformly sized particles. Therefore, we next utilized 
alternative strategy where we aimed to mimic the nanoparticle formulation 1 
protocol which produces particles with more homogenous size distribution and 
adapt it for in vivo settings (Figure 9, CCC). We assembled the particles at the 
same concentration as we did for formulation 1, lyophilized the complexes and 
reconstituted the specimen in a smaller volume to prepare higher concentration 
of cryo-concentrated complex (CCC, peptide concentration 400 µM at the same 
peptide: DNA charge ratio 4) formulation required for administration in vivo. 
According to DLS, CCC particles revealed markedly higher size homogeneity 
than the formulation 2 and around 98% of particles were around the desired size 
range (around 100 nm size) and more suitable for in vivo administration (Figure 
11). We thereafter analyzed morphology of CCC nanoparticle with TEM. After 
lyophilization, the CCC formulation sample contained mostly 50 nm-sized 
separate spherical particles (in the Paper II, Figure 5C). Both DLS and TEM 
results indicated that CCC formulation method can be utilized to produce 
particles with homogenous size distribution. 
After we had verified that CCC formulation method can be applied to 
prepare nanoparticles with homogenous size distribution we then aimed to 
investigate the stability and bioactivity of CCC formulated particles. As the 
stability of nanoparticles in the blood stream is crucial for their utilization, we 
analyzed the resistance of the nanoparticles to protease digestion. CCC 
nanoparticles demonstrated slightly higher resistance to protease digestion 
compared to the standard formulation, thus indicating that CCC nanoparticles 
are more stable and tightly packed and therefore more suitable for the systemic 





Figure 11. DLS analyzis of samples indicates that CCC formulation strategy produces 
non-conglomerating nanoparticles with homogenous size distribution compare to 
standard formulation 2 method. Particles obtained by complex formulation method 2 are 
represented with a dashed red line, and the cryo-concentration complex (CCC) 
formulation strategy is illustrated with a green line. The dotted darker green line shows 
the size distribution of CCC particles after incubation for 60 min. 
 
Subsequently, confirming that CCC formulation yields more uniform and stable 
particles we continued with transfection studies. CCC particles exhibited similar 
delivery efficiency in cell culture as standard formulation 1. These results 
encouraged us to investigate the CCC bioactivity in vivo. Interestingly, CCC 
particles were twice as effective in transfecting lung tissue compared to standard 
formulation 2 treatments (Figure 12). The fact that the transfection efficacy 
increases after CCC formulation method offers a very promising strategy to 
generate efficient transfection reagent with uniform size distribution of particles. 
Moreover, these nanoparticles can be stored in lyophilized state (at least seven 
days as shown in the Paper I, Figure 5) at room temperature until needed and 
after convenient reconstitution in water these particles still maintain their 
homogenous size distribution (Figure 11) and high systemic in vivo gene delivery 
efficacy (Figure 12).  
Because the filtered samples where we managed to produce smaller particles 
with more homogenous size distribution showed the reduced bioactivity, we 
hypothesized that maybe the larger conglomerates facilitate the transfection. 
There have been reports that sedimentation of larger aggregated nanoparticles 
can enhance the transfection in vitro(175). It has also been demonstrated that 
conglomerated large particles tend to accumulate within capillaries of the 
lung(74). These studies might help to explain why the filtered fraction of nano-
particles that contains homogenous small nanoparticles exhibit reduced 
bioactivity in lungs. To investigate the importance of the size and the size distri-
bution of the particle on transfection efficacy, we increased the conglomeration 
of the CCC particles by incubating these at room temperature for 60 min, 
instead of using immediately after the reconstitution of nanocomplexes. DLS 
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shows that incubation of CCC particles for 60 min induces positive skew to the 
size distribution, increasing the fraction with larger size (Figure 11). This 
incubation encouraged aggregation of particles up to 13% of overall particle 
population according to DLS. Increased conglomeration however decreased 
transfection of CCC particles back to the similar efficacy as was detected after 
treatment with the standard formulation 2 particles (Figure 12). This suggests 





Figure 12. CCC formulation strategy significantly improved the systemic in vivo gene 
delivery whereas filtration of particles reduced the transfection. Transfection efficacy in 
vivo of standard formulation 2, CCC and filtered formulation 2 nanoparticles at CR4 
and 20μg pDNA. The data is from at least three representative experiments performed 
in triplicate, presented as mean ± SEM, *P < 0.05 (Student t-test, two-tailed 
distribution, two-sample unequal variance. 
 
Conclusively, in the Paper II we developed novel nanoparticle formulation using 
cryo-concentration that yields stable particles with homogenous size distribution 




4.3. Incorporation of iron oxide particles to improve the 
efficacy and specificity of peptide vectors 
The important obstacle to overcome is the non-targeted delivery of nano-
particles. This off-targeted uptake of nanoparticles could increase side effects 
and reduce the efficacy of treatment. Magnetic nanoparticles can be used to create 
selective targeting drug delivery systems(157). Recent studies have shown that 
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incorporation of magnetic nanoparticles can enhance cell or tissue specific 
uptake of nanoparticles in the presence of magnetic field(157,161,176). In the 
Paper III, we aimed to study whether these magnetic particles could be incorpo-
rated into our CPP- nucleic acid formulations. We incorporated iron oxide 
nanoparticles into CPP and nucleic acid particles to investigate the physico-
chemical properties of the formulated particles. The future goal of this study is 
to improve the efficacy and specificity of the CCP transfection through the 
incorporation of magnetic particles and utilization of magnetic field.  
We used our previously designed effective PepFect14 peptide as the most 
thoroughly described peptide from our designed CPPs and its analogues to form 
nanoparticles with magnetic iron oxide and nucleic acid (NA).  
First, we studied the ability of PF analogues to complex Fe3O4 and nucleic 
acids. Most PF analogues were able to form stable nanoparticles with Fe3O4 and 
nucleic acids as these formulations displayed zeta potential ≥30 mV or ≤ – 30 mV 
which is usually considered a good indicator for stable colloidal dispersions. In 
addition to describing stability of particles, surface charge is important for their 
cellular uptake. Nanoparticles with positive surface charge are typically taken 
up by the cells more efficiently compared to negatively charged counter-
parts(74). This can be mainly due to the greater interaction between nano-
particles and negatively charged plasma membrane. Most PF analogue formu-
lations with Fe3O4 and nucleic acids indeed had the positive surface charge. 
Taken together these results demonstrate that iron oxide can be incorporated 
into our PF/NA formulations to produce stable nanoparticles which is essential 
for the efficient transfection. 
Next, after the characterization of the size and surface charge of Fe3O4 
/PF/NA particles we continued to investigate their transfection efficacy. First, 
we tested the transfection efficacy of Fe3O4 /PF/NA particles in the cell culture. 
We studied the ability of Fe3O4 /PF particles to enhance plasmid delivery and 
three PF analogues (PF221, PF222 and PF223) complexed with Fe3O4 demon-
strated 2-100-fold higher plasmid transfection compared to standard PF/pDNA 
particles. Thereafter, we studied SCO delivery and the most effective one from 
the screened PF peptides was the parent peptide Fe3O4 /PF14 particles which 
increased splice correction 4-times compared to standard PF14/SCO complexes. 
Fe3O4 /PF14 /siRNA particles also demonstrated highest downregulation com-
pared to other Fe3O4 /PF/siRNA formulations and standard PF14/siRNA 
particles. As there was no magnetic field involved with these transfection 
studies this increased efficacy might be caused because of the enhanced sedi-
mentation of the particles after the addition of Fe3O4. We concluded that  
PF-nucleic acid formulation can be further complexed with Fe3O4 to signi-
ficantly enhance the biological activity in the cell culture. 
The internalization mechanism of CPP-nucleic acid particles is still debat-
able, but the likeliest entering pathway of particles is thought to be endocytosis, 
although energy-independent translocation has been described. The internali-
zation mechanism of vectors modified with magnetic particles are thought to be 
remain the same. Huth et al.(177) and Sauer et al.(178) have studied the 
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internalization of magnetic particles coated with PEI polyplexes or lipoplexes, 
respectively. Both studies concluded that the addition of Fe3O4 did not change 
the internalization mechanism of these vectors and the coated magnetic particles 
still used mainly endocytosis to enter cells. We used therefore confocal micros-
copy to investigate the cellular uptake of our Fe3O4 /PF/NA particles. Indeed, 
we similarly concluded that the incorporation of Fe3O4 did not alter the cellular 
uptake compared to conventional PF/NA particles without the magnetic particles. 
Finally, we decided to use PF14, which has been extensively described and 
utilized in vivo already, to form complexes with Fe3O4 for systemic delivery of 
pDNA. The highest reporter gene expression was detected in lungs and liver 
tissue (in the Paper III, Figure 8). Incorporation of Fe3O4 decreased the lumi-
nescence signal 5- and 20-fold in lung and liver respectively. Although 
incorporation of Fe3O4 into PF14/pDNA particles reduced the bioactivity in the 
analyzed tissues further study is necessary to assess usefulness of iron oxide for 
tissue specific targeting via magnetic field.  
Taken together, we described Fe3O4 /PF/nucleic acid particles and showed 
the effectiveness of incorporation of iron oxide into standard PF/NA complexes 
to increase the transfection in cell culture. In vivo results demonstrate that 
Fe3O4 /PF14/pDNA bioactivity is not entirely diminished and application of 
magnetic field could be used to enhance particle accumulation and biological 











The main aim for this research was to design more efficient and safer formu-
lations of CPP/nucleic acid particles for the systemic in vivo delivery of nucleic 
acids.  
The key results can be concluded as described below. 
 
Paper I 
 Optimization of the secondary amphipathicity and charge of the NickFect 
peptide analogues improved the transfection efficiency.  
 Novel peptide NF55 formed stable nanoparticles with DNA that were 
resistant to protease degradation. 
 NF55 mediated DNA delivery in vivo with excellent gene induction effi-
ciency that is comparable to the commercial transfection reagents currently 
available offering a safer alternative for the systemic in vivo gene delivery. 
 NF55/DNA nanoparticles demonstrated increased tumor transfection in 
various mouse tumor models. Efficiency of NF55 to deliver DNA into tumor 
tissue increased even further after incorporation of PEG2000 polymer. 
 Solid formulation of NF55/DNA particles displayed a good stability profile 
without additives or special storage conditions. 
 
Paper II 
 Filtration of the NF55/DNA nanoparticles successfully removed large 
aggregates and increased the homogeneity of the particle size distribution. 
 Cryo-concentration formulation strategy of NF55/DNA particles produced 
non-conglomerating nanoparticles with uniform size, increased resistance 
to protease degradation and significantly improved bioactivity in vivo.  
 
Paper III 
 PF peptides were able to form stable complexes with nucleic acid and 
Fe3O4 particles. 
 Incorporation of Fe3O4 particles significantly enhanced PF peptides ability 
to transfect nucleic acids in cell culture. 
 Application of magnetic field might be used in future to increase the 








6. SUMMARY IN ESTONIAN 
Genoomika ja sekveneerimismeetodite areng on täiendanud meie teadmisi 
geneetikast ning geneetilisetest haigustest. Geneetiliste haiguste tekkepõhjuste 
mõistmine võimaldab meil sünteesida erinevalt modifitseeritud seerum-stabiil-
seid terapeutilisi nukleiinhappeid, reguleerimaks spetsiifiliselt mingi konkreetse 
geeni avaldumist. Nii on võimalik rakendada geeniteraapiat ning taastada 
kahjustunud või puuduva geeni funktsioon või hoopis vaigistada ebanormaalselt 
üle-ekspresseeruv geen. Kahjuks takistab nende nukleiinhapete edukat kasuta-
mist antud terapeutiliste molekulide laeng ja suurus, mis vähendab oluliselt 
nende biomolekulide jõudmist kahjustunud koe rakkudesse.  
Nukleiinhapete rakkudesse sisenemise efektiivsuse tõstmiseks kasutatakse 
mitmesuguseid geenivektoreid, mida võib jagada viiruslikeks ja mitte-viirus-
likeks vektorites. Kuigi viirusvektorid on hetkel kasutatavatest vektoritest ühed 
efektiivseimad ning üle 69% kliinilistes katsetes kasutatavatest geenivektoritest 
on just viirusvektorid, siis segab nende kasutamistveelgi edukamat rakendamist 
vektorite võimalik immunogeensus ja transfekteeritava nukleiinhape suuruse 
piirang. Mitte-viiruslikud vektorid on küll madalama transfektsiooni efektiiv-
susega, kuid nad on võrreldes viirusvektoritega tavaliselt vähem toksilisemad.  
Üheks mitte-viiruslikuks transfektsioonivektoriks on rakku sisenevad pep-
tiidid (RSP). RSP-d on tavaliselt kuni 30 aminohappe pikkused katioonsed 
ja/või amfipaatsed peptiidid. RSP saab siduda kovalentselt või mittekovalentselt 
mitmesuguste terapeutiliste ühenditega (nukleiinhapetega, valkudega, peptiidi-
dega jt molekulidega), et suurendada nende transporti rakkudesse nii in vitro, 
kui ka in vivo. Peamiseks probleemiks RSP kasutamisel on nende peptiidide 
vähene transfektsiooni efektiivsus in vivo. Lisaks on RSP tavaliselt vaja modi-
fitseerida, et muuta neid selektiivseks konkreetse koe ja rakutüübi suhtes, 
vähendades seeläbi võimalike kõrvalmõjude tekke riski. Samuti on oluline 
kontrollida moodustatud RSP-nukleiinhappe osakeste füsiko-keemilisi omadusi, 
sest ka sellest sõltub osakeste biodistributsioon organismis. Nukleiinhapete 
transfektsiooniks kasutatakse enamasti mittekovalentset peptiidiga seondamist, 
mis on odavam ning lihtsam, kuid selle meetodiga moodustunud nanopartiklid 
on küll stabiilsed ent väga heterogeense suurusjaotusega. Selline erinev nano-
partiklite suuruse distributsioon mõjutab nii rakukultuuri kui ka in vivo tule-
musi. Erineva suurusega osakesed akumuleeruvad erinevatesse organitesse ja 
ekskreteeritakse organismist erineva kiirusega. Samuti sõltub osakeste suurusest 
kui hästi tuntakse partikkel ära retikuloendoteliaalsüsteemi poolt ning kui pikk 
on komplekside poolväärtusaeg seerumis. Lisaks suurendab selline suurusest 
tulenev mittespetsiifiline osakeste kuhjumine kõrvalnähtude teket. Seega on 
oluline leida õige formuleerimise tehnika, et kontrollida paremini osakeste 
suurusjaotust. 
Antud doktoritöö eesmärk oli valmistada efektiivseks ja ohutuks süsteem-
seks in vivo manustamiseks mõeldud RSP -nukleiinhappe formulatsioon. 
51 
Esimeses töös disainiti NickFect peptiidide ja nukleiinhappega moodustunud 
komplekside füsiko-keemiliste omaduste ning sisenemismehhanismide põhjal 
uued NickFect peptiidi analoogid. Optimeerides nii peptiidi laengut kui ka amfi-
paatsust, sünteesiti NickFect55 peptiidi, mis moodustab nukleiinhappega pro-
teaasitöötlusele vastupidavaid stabiilseid osakesi. See on oluline NF55 nano-
partikli poolväärtusaja suurendamiseks seerumis. Lisaks suurendas NF55 pep-
tiid oluliselt DNA transfektsiooni nii rakukultuuris, kui ka in vivo mitmes hiire 
vähkkasvaja mudelis.  
Teises artiklis keskenduti NF55-DNA osakeste formulatsiooni modifitseeri-
misele, et komplekside kasutamine oleks ohutum ja efektiivsem. Selgus, et in 
vivo kasutamiseks mõeldud formulatsioonis on vaid 1/3 tekkinud osakeste dia-
meeter alla 200 nm ning seega on umbes 30% osakestest ainult sobilik süsteem-
seks manustamiseks. Osakeste heterogeense suurusjaotuse vähendamiseks ja 
aglomeratsiooni vältimiseks filtreeriti või lüofiliseeriti osakesi väiksemas kon-
sentratsioonis (CCC-cryo-concentrated complex formulation). Mõlemad mee-
todid vähendasid märgatavalt partiklite aglomeerumist ning suurendasid väik-
sema läbimõõduga (<200 nm) osakeste osakaalu. Kui filtratsioon vähendas 
nanopartiklite bioloogilist aktiivsust, siis CCC formulatsiooni tehnika suurendas 
oluliselt moodustunud osakeste in vivo transfektsiooni ning stabiilsust proteaasi 
töötlusele. 
Kolmandas töös lisati RSP ja nukleiinhappe kompleksidele magnetilisi raua-
oksiidi osakesi suurendamaks transfektsiooni raku-ning koespetsiifilisust. Uuriti 
PepFect peptiidide võimet moodustada osakesi erinevate nukleiinhapete ja mag-
netiliste Fe3O4 partiklitega. Fe3O4 lisamine PF-nukleiinhapete kompleksidesse ei 
vähendanud osakeste stabiilsust ning suurendas oluliselt bioloogilist aktiivsust 
rakukultuuris. Samas näitasid loomkatsed, et rauaühendite lisamine vähendab 
transfektsiooni. Edasine uuring koos magnetvälja kasutamisega on vajalik, et 
selgitada kas magnetilisi osakesi saaks kasutada konkreetse organi transfekt-
siooniks. 
Kokkuvõtvalt valmistati antud doktoritöös rakkusisenev peptiid ning formu-
latsiooni meetod, millega on võimalik moodustada stabiilseid homogeense 
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